Elevance Health, Inc. with ticker code (ELV) now have 20 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $625.00 and $465.00 calculating the average target share price we see $530.52. (at the time of writing). Now with the previous closing price of $419.04 this now indicates there is a potential upside of 26.6%. The 50 day moving average now sits at $514.83 and the 200 moving average now moves to $517.01. The market cap for the company is 98.61B. Currently the stock stands at: $425.27 USD
The potential market cap would be $124,849,137,880 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.48, revenue per share of $747.41 and a 5.84% return on assets.
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
